Welcome to LookChem.com Sign In|Join Free

CAS

  • or
1-METHYLPIPERIDIN-3-YL METHANESULFONATE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

583814-96-4 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 583814-96-4 Structure
  • Basic information

    1. Product Name: 1-METHYLPIPERIDIN-3-YL METHANESULFONATE
    2. Synonyms: 1-METHYLPIPERIDIN-3-YL METHANESULFONATE
    3. CAS NO:583814-96-4
    4. Molecular Formula: C7H15NO3S
    5. Molecular Weight: 193.26
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 583814-96-4.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 1-METHYLPIPERIDIN-3-YL METHANESULFONATE(CAS DataBase Reference)
    10. NIST Chemistry Reference: 1-METHYLPIPERIDIN-3-YL METHANESULFONATE(583814-96-4)
    11. EPA Substance Registry System: 1-METHYLPIPERIDIN-3-YL METHANESULFONATE(583814-96-4)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 583814-96-4(Hazardous Substances Data)

583814-96-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 583814-96-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,8,3,8,1 and 4 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 583814-96:
(8*5)+(7*8)+(6*3)+(5*8)+(4*1)+(3*4)+(2*9)+(1*6)=194
194 % 10 = 4
So 583814-96-4 is a valid CAS Registry Number.

583814-96-4Relevant articles and documents

QUINAZOLINONES AS PARP14 INHIBITORS

-

Paragraph 0298, (2019/07/10)

The present invention relates to quinazolinones and related compounds which are inhibitors of PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.

Selectivity Optimization of Substituted 1,2,3-Triazoles as α7 Nicotinic Acetylcholine Receptor Agonists

Arunrungvichian, Kuntarat,Fokin, Valery V.,Vajragupta, Opa,Taylor, Palmer

, p. 1317 - 1330 (2015/09/01)

Three series of substituted anti-1,2,3-triazoles (IND, PPRD, and QND), synthesized by cycloaddition from azide and alkyne building blocks, were designed to enhance selectivity and potency profiles of a lead α7 nicotinic acetylcholine receptor (α7-nAChR) agonist, TTIn-1. Designed compounds were synthesized and screened for affinity by a radioligand binding assay. Their functional characterization as agonists and antagonists was performed by fluorescence resonance energy transfer assay using cell lines expressing transfected cDNAs, α7-nAChRs, α4β2-nAChRs, and 5HT3A receptors, and a fluorescence cell reporter. In the IND series, a tropane ring of TTIn-1, substituted at N1, was replaced by mono- and bicyclic amines to vary length and conformational flexibility of a carbon linker between nitrogen atom and N1 of the triazole. Compounds with a two-carbon atom linker optimized binding with Kds at the submicromolar level. Further modification at the hydrophobic indole of TTIn-1 was made in PPRD and QND series by fixing the amine center with the highest affinity building blocks in the IND series. Compounds from IND and PPRD series are selective as agonists for the α7-nAChRs over α4β2-nAChRs and 5HT3A receptors. Lead compounds in the three series have EC50s between 28 and 260 nM. Based on the EC50, affinity, and selectivity determined from the binding and cellular responses, two of the leads have been advanced to behavioral studies described in the companion article (DOI: 10.1021/acschemneuro.5b00059).

NOVEL MCH RECEPTOR ANTAGONISTS

-

Page/Page column 76-77, (2008/06/13)

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1, R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 583814-96-4